or Try an Advanced Search...

    Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 4.19 2.44% 0.10
    ZNTL closed up 2.44 percent on Monday, July 1, 2024, on 60 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ZNTL trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 2.44%
    Narrow Range Bar Range Contraction 2.44%
    Wide Bands Range Expansion 2.44%
    Oversold Stochastic Weakness 2.44%
    Narrow Range Bar Range Contraction -0.24%
    Wide Bands Range Expansion -0.24%
    Oversold Stochastic Weakness -0.24%
    Older End-of-Day Signals for ZNTL ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 9 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Up 3% about 9 hours ago
    Up 2% about 10 hours ago
    Down 1% about 11 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ZNTL Chart by TradingView
    Basic chart:

    Profile

    Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer

    Is ZNTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 (ZNTL) - Analyzing Zentalis Pharma's Short Interest
    Jun 20 Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
    Jun 19 Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
    Jun 19 FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
    Jun 18 US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth
    Jun 18 Top Midday Decliners
    Jun 18 Zentalis falls after FDA partial clinical hold on lead asset
    Jun 18 Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
    Jun 4 We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
    Jun 1 Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
    See more ZNTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.03
    52 Week Low 3.9301
    Average Volume 1,424,251
    200-Day Moving Average 13.62
    50-Day Moving Average 10.16
    20-Day Moving Average 7.64
    10-Day Moving Average 4.80
    Average True Range 0.81
    RSI (14) 20.63
    ADX 44.28
    +DI 7.05
    -DI 41.26
    Chandelier Exit (Long, 3 ATRs) 10.58
    Chandelier Exit (Short, 3 ATRs) 6.35
    Upper Bollinger Bands 13.72
    Lower Bollinger Band 1.56
    Percent B (%b) 0.22
    BandWidth 159.20
    MACD Line -2.03
    MACD Signal Line -1.73
    MACD Histogram -0.2977
    Fundamentals Value
    Market Cap 296.51 Million
    Num Shares 70.8 Million
    EPS -4.56
    Price-to-Earnings (P/E) Ratio -0.92
    Price-to-Sales 0.00
    Price-to-Book 1.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.51
    Resistance 3 (R3) 4.49 4.38 4.45
    Resistance 2 (R2) 4.38 4.30 4.38 4.43
    Resistance 1 (R1) 4.28 4.25 4.33 4.30 4.42
    Pivot Point 4.17 4.17 4.19 4.17 4.17
    Support 1 (S1) 4.07 4.09 4.12 4.09 3.96
    Support 2 (S2) 3.96 4.04 3.96 3.95
    Support 3 (S3) 3.86 3.96 3.93
    Support 4 (S4) 3.88